Profile
Azenta provides automated sample management and multiomics solutions for life sciences research and biobanking.
Azima, Inc. (NASDAQ: AZTA) is a life sciences company specializing in sample management and multiomics solutions. The company operates in two primary segments: Sample Management Solutions, which includes automated stores, cryogenic systems, and sample storage services, and Multiomics, which focuses on next-generation sequencing, gene synthesis, and Sanger sequencing. Azenta has faced recent challenges, with Q1 2026 revenue from continuing operations at $149 million, up only 1% year-over-year, and organic revenue declining by 1%.
The company reported an operating loss of $7.2 million and an adjusted EBITDA margin of 8.5%, down from 13.0% in the previous quarter. Azenta is in the process of selling its B Medical Systems business, which is treated as discontinued operations. The company has revised its fiscal 2026 guidance, now expecting total revenue from continuing operations between $603 million and $621 million, with organic revenue growth ranging from -2% to +1%.
Azenta's leadership emphasizes operational discipline and a focus on recurring revenue offerings, but execution gaps and a cautious demand environment, particularly in North America, have impacted performance. The company has extended its long-range plan timeline from 2028 to 2029 to account for these challenges.
Who buys this
- Pharmaceutical and biotech companies
- Academic and government research institutions
- Clinical diagnostic laboratories
- Biobanks and biorepositories
- Agriculture and food science researchers
Strengths and what to watch
Strengths
- Recurring revenue streams from sample storage and consumables
- Diversified portfolio across sample management and multiomics
- Strong position in biobanking and cold chain sample management
Watch for
- Declining margins with Q1 2026 adjusted EBITDA down 39% quarter-over-quarter
- Execution challenges in Multiomics segment turnaround
- Revenue guidance reduction from 3-5% growth to -2% to +1% for FY2026
Recent moves
Key Information
- Founded
- 1966
Frequently Asked Questions
What does Azenta do?
Azenta provides automated sample management and multiomics solutions for life sciences research. Their offerings include biobanking storage systems, cold chain management, and genomic sequencing services, serving pharmaceutical companies, research institutions, and clinical labs with sample handling and analysis technologies.
How is Azenta performing financially in 2026?
Azenta reported Q1 2026 revenue of $149 million, up just 1% year-over-year, with an operating loss of $7.2 million. The company revised its full-year revenue guidance downward to -2% to +1% growth, citing execution challenges and soft demand in North America.
What are Azenta's main product segments?
Azenta operates in two segments: Sample Management Solutions (automated storage and cryogenic systems) and Multiomics (next-gen sequencing and gene synthesis). These serve biobanking, pharmaceutical research, and clinical diagnostics needs with integrated sample handling and genomic analysis technologies.
Who uses Azenta's services?
Azenta's customers include pharmaceutical companies, biotech firms, academic research centers, clinical diagnostic labs, and agricultural researchers. Their solutions support drug discovery, genomic studies, and biological sample preservation across these sectors with specialized storage and analysis platforms.
Why did Azenta lower its 2026 guidance?
Azenta reduced its revenue outlook due to operational execution gaps, declining margins (EBITDA down to 8.5%), and weaker demand in core markets. The company extended its strategic plan timeline to 2029 to address these challenges while divesting non-core assets like B Medical Systems.
What makes Azenta different in life sciences?
Azenta combines automated sample management with multiomics capabilities, offering end-to-end solutions from biobanking to genomic analysis. Their strength lies in integrated cold chain systems and recurring revenue from storage services, though recent financial pressures highlight execution challenges in scaling these technologies.
Sources
- investors.azenta.com — Q1 2026 financial results and segment performance
- www.prnewswire.com — Q2 2026 results and updated guidance
- techcrunch.com — Context on 2025 tech industry layoffs
- www.businessinsider.com — Industry-wide layoff trends in 2025